GlassScriptPhysician profile
Michael A White
NPI 1265690804
$5,918.90
in general payments reported to CMS, 2019-2025
30 companies · $1,304 in 2025
The $1,304 reported for 2025 was more than what 75% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,381 · 2020: $424 · 2021: $613 · 2022: $344 · 2023: $171 · 2024: $1,682 · 2025: $1,304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,287 · Food and Beverage: $870.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,287.46 |
| Food and Beverage | $870.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Histosonics, INC. | $2,307.25 | 2024-2025 | |
| Medical Device Business Services, INC. | $952.22 | 2019 | |
| Davol INC. | $617.04 | 2020-2025 | Phasix Mesh |
| Ethicon US, LLC | $415.05 | 2019-2025 | Echelon Flex, N/A |
| Medtronic, INC. | $325.85 | 2021-2025 | Transorb, Signia, Progrip |
| Mimedx Group, INC. | $218.08 | 2024-2025 | |
| Covidien LP | $209.88 | 2019-2020 | |
| Biom'Up France Sas | $165.00 | 2021 | |
| Novo Nordisk INC | $102.27 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $95.57 | 2020-2022 | |
| Abbvie INC. | $84.66 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $54.53 | 2019-2020 | |
| Allergan, INC. | $38.50 | 2019-2022 | |
| Innocoll Pharmaceuticals Limited | $36.54 | 2021 | |
| Becton, Dickinson and Company | $28.21 | 2025 | Arista |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| W. L. Gore & Associates, INC. | $26.30 | 2019 | |
| Abiomed | $24.86 | 2024 | Impella |
| Tela Bio, INC. | $24.70 | 2021 | |
| Alcresta Therapeutics, INC. | $20.75 | 2025 | Relizorb |
| Apollo Endosurgery US INC | $19.57 | 2023 | Overstitch Endoscopic Suturing System |
| Mallinckrodt Hospital Products INC. | $19.52 | 2020 | |
| Heron Therapeutics, INC. | $18.49 | 2022 | |
| Boston Scientific Corporation | $17.14 | 2020 | |
| Acell, INC. | $17.04 | 2019 | |
| Trevena, INC. | $14.79 | 2022 | |
| Baxter Healthcare | $14.18 | 2020 | |
| Smith+Nephew, INC. | $13.15 | 2022 | |
| Endo Pharmaceuticals INC. | $13.12 | 2019 | |
| Osiris Therapeutics INC. | $12.59 | 2019 | |
| Nestle Healthcare Nutrition INC. | $12.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.